Should Dick’s Still Be Increasing the Number of Its Stores?
Retailers have been hit hard during the pandemic, and many have shut their brick-and-mortar locations. However, Dick’s Sporting Goods is expanding its nationwide footprint.
All Work
Chris Lange
Why Solid Bio’s Future Just Got a Lot Brighter
Solid Biosciences shares more than doubled on Thursday after the company announced a key update from the FDA.
Why the Bed Bath & Beyond Turnaround Finally Has Come True
Bed Bath & Beyond reported better than expected fiscal second-quarter financial results before the markets opened on Thursday.
Did Palantir’s Market Debut Live Up to the Hype?
Sofftware platform maker Palantir Technologies came public Wednesday through a direct listing that valued the company at about $22 billion.
Why Analysts Are Cautiously Optimistic About Micron After Earnings
Although investors were disappointed with the Micron Technology quarterly results, analysts looked further out and were fairly positive.
Why Pizza Giants Will Keep Thriving After the Pandemic
The name of the game for restaurants during the government-mandated COVID-19 lockdowns has been delivery, and nobody does that better than pizza companies.
2 Big Positive Developments in the COVID-19 Vaccine Race
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Beyond Meat’s Distribution Expansion With Walmart Is Only Natural
Beyond Meat shares hit a multiyear high on Tuesday after the company announced that it would expand its long-standing relationship with Walmart.
Why Aptorum Stock Absolutely Took Off on Tuesday
Aptorum shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases.
McCormick Announces Stock Split and Earnings Beat
McCormick reported better than expected second-quarter financial results and a 2-for-1 stock split before the markets opened on Tuesday.
Genfit and Lab Corp Partner Up For NASH Liver Test
Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH | LH Price Prediction). This agreement is ultimately for Genfit’s technology to…
Eiger BioPharmaceuticals COVID-19 Study Fails to Live Up to Expectations
Eiger BioPharmaceuticals has announced disappointing results from a study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.
Why This Tesla Deal Is Huge for Piedmont Lithium
Piedmont Lithium has announced a binding agreement with Tesla to supply spodumene concentrate from its North Carolina deposit. Shares of Piedmont nearly tripled on the news.
Should Aquestive Therapeutics Be Worried About This FDA Response?
Aquestive Therapeutics said that it had received a negative response from the FDA concerning its treatment for the management of seizure clusters.
Is the FDA’s Hold on Inovio’s COVID-19 Vaccine Study Too Much?
Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.
Conagra, Constellation Brands, Micron, Pepsi and More Major Earnings This Week
24/7 Wall St. has previewed PepsiCo, Micron Technology and some of the other key companies expected to report results this week.
Why This Analyst Sees Nearly 30% More Upside in DraftKings
As more states loosen gambling restrictions, Argus expects DraftKings to benefit from its market leadership.
Biotech Short Sellers Hike Their Bets
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Short Sellers Get a Little Mixed Up on Semiconductors
The September 15 short interest data have been compared with the previous report, and short interest moves were mixed on most of these selected semiconductor stocks.
Why Amgen Is Called to Outperform Large-Cap Biotechs
Credit Suisse has set an Outperform rating and $290 price target on Amgen shares. That target implies more than 20% upside to the stock's recent trading price.